Organon Launched Science Fiction Marketing for Vtama

The pharmaceutical company introduced a new campaign featuring alien-themed spots to promote its skin treatment.

Updated on Oct. 1, 2026 in Advertising

A small jar of medical cream sitting on a sterile, reflective laboratory workbench in a modern clinical environment. — Organon has launched a new marketing campaign for its dermatology treatment Vtama, utilizing science-fiction themes to reach clinicians in the competitive U.S. pharmaceutical market. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies use science fiction-themed entertainment to market medical treatments to doctors?

Organon has unveiled a science fiction-themed marketing campaign to promote the dermatological cream Vtama. The initiative aims to distinguish the treatment within the competitive medical dermatology market through a series of alien-focused video advertisements.

Why it matters

The company seeks to educate clinicians on the specific clinical utility of Vtama following its recent indication expansion. By utilizing a creative narrative, Organon aims to improve brand recognition among dermatologists and allergists.

Organon recorded $128 million in Vtama sales during 2025, falling short of its $150 million target. The firm previously invested $1.2 billion to acquire Dermavant and currently maintains advisory boards featuring 120 dermatologists and allergists.

The players

Organon

This global healthcare company focuses on women's health and recently expanded its portfolio into medical dermatology.

Dermavant

This biopharmaceutical company specializes in developing innovative treatments for inflammatory skin diseases and was acquired by Organon.

The details

The campaign uses the tagline 'it's not science fiction, its Skin Science' and features video advertisements where aliens investigate the cream. Organon is supporting this rollout through a multi-channel media strategy, including social-first video, digital outreach, and in-office materials.

Vtama first entered the market for plaque psoriasis in 2022.
Organon acquired Dermavant in 2024.
Vtama received approval for atopic dermatitis in late 2024.

Advertising
Sept. 29
Skyrizi Led National TV Pharma Advertising in August
Healthcare
Sept. 30
Acrotech Biopharma Launched ADQUEY Ointment
Arthritis
Sept. 28
Takeda Reported Positive Psoriasis Drug Trial Results

Market Landscape

This marketing push follows the 2024 acquisition of Dermavant as part of an effort to integrate the subsidiary's primary asset into broader commercial operations. The company is positioning the product to capture market share within the crowded landscape of dermatological treatments.

The campaign aims to clarify the clinical role of Vtama, which may influence the treatment options clinicians discuss with patients suffering from plaque psoriasis or atopic dermatitis. Patients should consult their healthcare provider to determine if this medication aligns with their specific dermatological needs.

The takeaway

Pharmaceutical marketing often shifts toward creative narratives to cut through the density of competing medical products. Understanding these branding strategies can help patients identify when a new marketing push is centered around existing or newly indicated treatments.